treatment and two&#45

A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Amisulpride FCT (400 mg) relative to Solian(R) 400 mg in healthy Thai volunteers under fasting condition

Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Levonorgestrel Tablets (1.5 mg) relative to POSTINOR 1® in healthy Thai female volunteers under fasting condition, LEV-006-19

A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of NUCOXIA 120 (Etoricoxib 120 mg tablets) relative to Arcoxia® 120 mg (Etoricoxib, MSD) tablets in healthy Thai volunteers under fasting condition

Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Gabapentin Capsule (300 mg) relative to NEURONTINTM 300 mg in healthy Thai volunteers under fasting condition

A Bioequivalence study of a randomized, open-label, single dose, fully replicate crossover design with four-period, two-treatment and two-sequence of Atorvastatin 80 mg tablets relative to Lipitor(R) 80 mg tablets in healthy Thai volunteers under fasting condition

A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Ondansetron Tablets USP 8 mg of Cadila Healthcare Ltd., India relative to Zofran® 8 mg (Ondansetron Tablets 8 mg) of Novartis Pharmaceuticals UK Ltd, United Kingdom in healthy Thai volunteers under fasting condition

A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Pregabalin Capsules 75 mg of Cadila Healthcare Ltd., India relative to LYRICATM (Pregabalin) Capsules 75 mg of Pfizer Manufacturing Deutschland GmbH, Freiburg, Germany in healthy Thai volunteers under fasting condition

A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Levetiracetam Tablets USP 500 mg of Cadila Healthcare Ltd., India relative to Keppra® 500 mg (Levetiracetam Tablets USP 500 mg) of UCB Pharma SA Braine-LʽAlleud, Belgium in healthy Thai volunteers under fasting condition

A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Desloratadine Tablets USP 5 mg of Cadila Healthcare Ltd., India relative to Aerius*5 mg (Desloratadine Tablets 5 mg) of SCHERING - PLOUGH LABO N.V., HEIST-OP-DEN-BERG, Belgium in healthy Thai volunteers under fasting condition

A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Donepezil Hydrochloride Orodispersible Tablets USP 10 mg of Cadila Healthcare Limited, India relative to Aricept(R) Evess 10 mg (Donepezil Hydrochloride Orodispersible Tablets) of BUSHU PHARMACEUTICALS LTD. MISATO FACTORY, JAPAN in healthy Thai volunteers under fasting condition

A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Deferasirox 250 mg dispersible tablets relative to Exjade® 250 mg dispersible tablets in healthy Thai volunteers under fasting condition

A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Etoricoxib film-coated tablets, 120 mg relative to Arcoxia® 120 mg tablets in healthy Thai volunteers under fasting condition

A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Sitagliptin Tablets USP 100 mg of Cadila Healthcare Ltd., India relative to JanuviaTM 100 mg (Sitagliptin Tablets 100 mg) of MERCK SHARP & DOHME Ltd, The United Kingdom in healthy Thai volunteers under fasting condition

A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Etoricoxib 120 mg tablets relative to Arcoxia 120 mg tablets in healthy Thai volunteers under fasting condition (ETO-011-20)